Evidence map›Paper›PMID 26420863›Full record

ArticleDiabetes2015

American Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiome.

Clay F Semenkovich, Jayne Danska, Tamara Darsow, Jessica L Dunne, Curtis Huttenhower, Richard A Insel, Allison T McElvaine, Robert E Ratner, Alan R Shuldiner, Martin J Blaser

Open access · bronzeAbstract readConference Proceedings
In one paragraph

Article in Diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Effects ofBMJ open · 2017
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Frontiers in immunology · 2017
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. COMPUTATIONAL APPROACHES TO STUDY MICROBES AND MICROBIOMES.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2016
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Clay F SemenkovichWashington University School of Medicine, St. Louis, MO.
Jayne DanskaThe Hospital for Sick Children, Toronto, Canada.
Tamara DarsowAmerican Diabetes Association, Alexandria, VA.
Jessica L DunneJDRF, New York, NY.
Curtis HuttenhowerHarvard T.H. Chan School of Public Health, Boston, MA, and Broad Institute of MIT and Harvard, Cambridge, MA.
Richard A InselJDRF, New York, NY.
Allison T McElvaineAmerican Diabetes Association, Alexandria, VA amcelvaine@diabetes.org.
Robert E RatnerAmerican Diabetes Association, Alexandria, VA.
Alan R ShuldinerUniversity of Maryland School of Medicine, Baltimore, MD.
Martin J BlaserNew York University School of Medicine, New York, NY.
American Diabetes Association · USBreakthrough T1D · USBroad Institute · USHospital for Sick Children · CANew York University · USUniversity of Maryland, Baltimore · USWashington University in St. Louis · US

Funding

ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
Research BaseP30DK072488 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI MITCHELL, BRAXTON D, TAYLOR, SIMEON I. · 2005 to 2019
$17.3M
NCRR NIH HHS M01 RR002719NIDDK NIH HHS P30 DK072488
6 · The paper itself

Abstract

From 27-29 October 2014, more than 100 people gathered in Chicago, IL, to participate in a research symposium titled "Diabetes and the Microbiome," jointly sponsored by the American Diabetes Association and JDRF. The conference brought together international scholars and trainees from multiple disciplines, including microbiology, bioinformatics, endocrinology, metabolism, and immunology, to share the current understanding of host-microbe interactions and their influences on diabetes and metabolism. Notably, this gathering was the first to assemble specialists with distinct expertise in type 1 diabetes, type 2 diabetes, immunology, and microbiology with the goal of discussing and defining potential pathophysiologies linking the microbiome and diabetes. In addition to reviewing existing evidence in the field, speakers presented their own original research to provide a comprehensive view of the current understanding of the topics under discussion.Presentations and discussions throughout the conference reflected a number of important concepts. The microbiota in any host represent a complex ecosystem with a high degree of interindividual variability. Different microbial communities, comprising bacteria, archaea, viruses, and fungi, occupy separate niches in and on the human body. Individually and collectively, these microbes provide benefits to the host-including nutrient harvest from food and protection against pathogens. They are dynamically regulated by both host genes and the environment, and they critically influence both physiology and lifelong health. The objective of the symposium was to discuss the relationship between the host and the microbiome-the combination of microbiota and their biomolecular environment and ecology-specifically with regard to metabolic and immunological systems and to define the critical research needed to understand and potentially target the microbiome in the prevention and treatment of diabetes. In this report, we present meeting highlights in the following areas: 1) relationships between diabetes and the microbiome, 2) bioinformatic tools, resources, and study design considerations, 3) microbial programming of the immune system, 4) the microbiome and energy balance, 5) interventions, and 6) limitations, unanswered questions, and resource and policy needs.

Indexed as

Biomedical ResearchEvidence-Based MedicineGastrointestinal MicrobiomeModels, BiologicalPrecision MedicineAnimalsCombined Modality TherapyComputational BiologyDiabetes ComplicationsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansHypoglycemic AgentsHypoglycemic Agents

Identifiers

PMID26420863
PMCPMC4876761
OpenAlexW2172937589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.